Silence Therapeutics strengthens Management Team with the appointment of CEO
Advertisement
Silence Therapeutics plc announced that it has appointed Jeffery Scott Vick as Group CEO in order to strengthen its core management team as the Company seeks to expand its business partnerships.
Jeff Vick (45) is a B.S. chemistry graduate of the University of Virginia, USA, has a Masters Degree in Chemistry from the University of California, San Diego and an MBA from Stanford Graduate School of Business. Jeff has extensive international experience having worked in senior positions in the healthcare industry in both Europe and the USA. In his early career he gained experience as a business analyst and biotech venture capitalist and importantly he worked in the drug delivery sector for five years in senior management roles with DepoTech Corporation in the USA.
From 1998-2001, as Vice President Corporate Development for Cytovia Inc he was responsible for negotiating multi-million dollar collaborations in the biotech sector. In 2001 he moved to Europe to take up an appointment as Vice President Business Development at Genset S.A., which was subsequently sold to Serono at a substantial premium. In 2003 Jeff was appointed Vice President Corporate Development and Intellectual Property of Centelion SAS, which now is owned by Sanofi Aventis. There is no further information required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules.
Jeff will be based in London and work closely with Iain Ross, who will continue in his role as Executive Chairman. Jeff Vick has been granted options over 1,500,000 ordinary shares in Silence Therapeutics plc at an exercise price of 127p per share, being the mid-market price of the shares at the close of business on the day before his appointment.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Novel regulator inhibits toxic protein aggregates in Huntington's disease
Research demonstrates millions of plastic particles exist in cosmetic products
MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award
Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear
Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc. - Total alliance milestones more than double to over €400 million, plus royalties on worldwide sales
Dharmacon Named Best Reagent Company at RNAi-2004-Boston Meeting on RNA
to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment
Marine biomedicine researchers decode structure of promising sea compound - Novel natural product yielding potential new ways to fight diseases
The Medical Research Council and GATC Biotech sign Sequencing Contract
